iNova Pharmaceuticals has entered a deal to acquire a consumer healthcare brand portfolio primarily made up of the BETADINE® product franchise from Mundipharma International.
The acquisition will bolster the consumer healthcare platform of iNova and contribute to additional sales in high-growth regions.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOnce the acquisition is concluded, the consumer health product portfolio of iNova will account for more than 80% of its total sales of products.
The merged business will have an improved geographical footprint with broad coverage in Asia and the Middle East and an additional presence in Canada and Europe.
iNova Pharmaceuticals CEO Dan Spira stated: “Betadine has tremendous global brand equity with over 60 years of use by healthcare professionals and consumers worldwide.
“We see significant potential to build on this heritage and make it the most trusted antiseptic brand throughout iNova’s geographies.”
With a presence in more than 20 countries across Africa and the Asia-Pacific region, the firm focuses on products chiefly in the throat, cough and cold, natural health and skincare areas.
In January 2021, the European Commission adopted the recommendation of the European Medicines Agency’s committee for orphan medicinal products to grant orphan drug designation to Mundipharma and Cidara Therapeutics’ rezafungin to treat invasive candidiasis.
